ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/Low-Dose Dex +/- Isa in Patients With R/R Myeloma
By
ASH 2022 Conference Coverage
FEATURING
Paul Richardson
By
ASH 2022 Conference Coverage
FEATURING
Paul Richardson
Login to view comments.
Click here to Login